Evidence map›Paper›PMID 39820687›Full record

ArticleThe Journal of infectious diseases2025

Mpox: What Have We Learned and How Do We Better Prepare for the Future?

Seth D Judson, Chloe M Orkin, Kelly Gebo

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Mpox vaccine in the Philippines: the waiting continues, but until when?Therapeutic advances in vaccines and immunotherapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Seth D JudsonDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-9911-7839
Chloe M OrkinBlizard Institute and Sexual Health, HIV All East Research (SHARE) Collaborative, Queen Mary University of London, London, United Kingdom.
Kelly GeboDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Funding

RESEARCH TRAINING IN MICROBIAL DISEASEST32AI007291 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JOEL N BLANKSON, Sara Elizabeth Cosgrove · 1986 to 2026
$9.1M
NIAID NIH HHS T32 AI007291NIH HHS T32 AI007291-34
6 · The paper itself

Abstract

The global outbreak of clade IIb mpox in 2022-2023 changed our understanding of the epidemiology and prevention of mpox, simultaneously highlighting inequities in access to vaccines, diagnostics, and therapeutics. With the recent multinational spread of clade Ib mpox, it is important to revisit these lessons to improve future response. In September 2024, an international mpox symposium was held at Johns Hopkins University to discuss what we have learned and how to better prepare for the future. Here we highlight perspectives from that meeting and priorities for future mpox research.

Indexed as

Disease OutbreaksMpox, MonkeypoxGlobal HealthHumansdiagnosticsmonkeypoxmpoxtherapeuticstransmissionvaccines

Identifiers

PMID39820687
PMCPMC12349931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.